NEWS DETAIL

Essai COLOSOTO : Sotorasib + Panitumumab + 5-FU en traitement de première ligne du cancer colorectal porteur de la mutation KRAS G12C – Oncodaily

Essai COLOSOTO : Sotorasib + Panitumumab + 5-FU en traitement de première ligne du cancer colorectal porteur de la mutation KRAS G12C (Oncodaily)

Informations médicales July 2, 2026

Contenu integral de l article

COLOSOTO Trial: Sotorasib + Panitumumab + 5-FU as 1L Therapy in KRAS G12C Mutated Colorectal Cancer / cancer, cancer care, Cancer research, cancer treatment, , cancer, cancer care, Cancer research, cancer treatment, chemotherapy, colorectal cancer, COLOSOTO, KRAS G12C, OncoDaily, Oncology, Sotorasib, Target therapy

Produits lies a cet article

Ces produits ont ete automatiquement associes au titre, au resume et au contenu de l article.

Questions frequentes

Which products are related to this article?

The system matched these relevant products from the article content: Lucius Sotorasib – Acheter en ligne SOTOLDX Sotorasib 120 mg.

How can I view the medicines discussed in this article?

Use the related product cards below the article to review available specifications, prices, product information, and reviews.

Does this article replace advice from a doctor or pharmacist?

No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.